| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H26O2 |
| Molecular Weight | 298.4192 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CCC4=CC(=O)C=C(C)[C@]34C
InChI
InChIKey=PEPMWUSGRKINHX-TXTPUJOMSA-N
InChI=1S/C20H26O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h10-11,15-17H,4-9H2,1-3H3/t15-,16-,17-,19-,20-/m0/s1
| Molecular Formula | C20H26O2 |
| Molecular Weight | 298.4192 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Atamestane is a new, competitive, and irreversible inhibitor of estrogen biosynthesis. It is an aromatase inhibitor. Atamestane lacks other intrinsic hormonal or antihormonal activities and shows no inhibition of other cytochrome-P450 dependent enzymes of adrenal steroidogenesis. It had been in phase III clinical trial for the treatment of breast cancer and phase II for the treatment of benign prostatic hyperplasia. It was discontinued from development after an 865-patient trial in breast cancer showed no improvement in efficacy over letrozole.
